Literature DB >> 28751568

mTOR (Mechanistic Target of Rapamycin) Inhibition Decreases Mechanosignaling, Collagen Accumulation, and Stiffening of the Thoracic Aorta in Elastin-Deficient Mice.

Yang Jiao1, Guangxin Li1, Qingle Li1, Rahmat Ali1, Lingfeng Qin1, Wei Li1, Yibing Qyang1, Daniel M Greif1, Arnar Geirsson1, Jay D Humphrey1, George Tellides2.   

Abstract

OBJECTIVE: Elastin deficiency because of heterozygous loss of an ELN allele in Williams syndrome causes obstructive aortopathy characterized by medial thickening and fibrosis and consequent aortic stiffening. Previous work in Eln-null mice with a severe arterial phenotype showed that inhibition of mTOR (mechanistic target of rapamycin), a key regulator of cell growth, lessened the aortic obstruction but did not prevent early postnatal death. We investigated the effects of mTOR inhibition in Eln-null mice partially rescued by human ELN that manifest a less severe arterial phenotype and survive long term. APPROACH AND
RESULTS: Thoracic aortas of neonatal and juvenile mice with graded elastin deficiency exhibited increased signaling through both mTOR complex 1 and 2. Despite lower predicted wall stress, there was increased phosphorylation of focal adhesion kinase, suggestive of greater integrin activation, and increased transforming growth factor-β-signaling mediators, associated with increased collagen expression. Pharmacological blockade of mTOR by rapalogs did not improve luminal stenosis but reduced mechanosignaling (in delayed fashion after mTOR complex 1 inhibition), medial collagen accumulation, and stiffening of the aorta. Rapalog administration also retarded somatic growth, however, and precipitated neonatal deaths. Complementary, less-toxic strategies to inhibit mTOR via altered growth factor and nutrient responses were not effective.
CONCLUSIONS: In addition to previously demonstrated therapeutic benefits of rapalogs decreasing smooth muscle cell proliferation in the absence of elastin, we find that rapalogs also prevent aortic fibrosis and stiffening attributable to partial elastin deficiency. Our findings suggest that mTOR-sensitive perturbation of smooth muscle cell mechanosensing contributes to elastin aortopathy.
© 2017 American Heart Association, Inc.

Entities:  

Keywords:  aorta; collagen; elastin; everolimus; mice

Mesh:

Substances:

Year:  2017        PMID: 28751568      PMCID: PMC5574180          DOI: 10.1161/ATVBAHA.117.309653

Source DB:  PubMed          Journal:  Arterioscler Thromb Vasc Biol        ISSN: 1079-5642            Impact factor:   8.311


  37 in total

Review 1.  Integrin-regulated FAK-Src signaling in normal and cancer cells.

Authors:  Satyajit K Mitra; David D Schlaepfer
Journal:  Curr Opin Cell Biol       Date:  2006-08-17       Impact factor: 8.382

2.  Supravalvular aortic stenosis. Clinical and pathologic observations in six patients.

Authors:  W N O'Connor; J B Davis; R Geissler; C M Cottrill; J A Noonan; E P Todd
Journal:  Arch Pathol Lab Med       Date:  1985-02       Impact factor: 5.534

Review 3.  Integrin and growth factor receptor crosstalk.

Authors:  B P Eliceiri
Journal:  Circ Res       Date:  2001-12-07       Impact factor: 17.367

4.  Cell biology. Dysfunctional mechanosensing in aneurysms.

Authors:  Jay D Humphrey; Dianna M Milewicz; George Tellides; Martin A Schwartz
Journal:  Science       Date:  2014-05-02       Impact factor: 47.728

5.  Prolonged rapamycin treatment inhibits mTORC2 assembly and Akt/PKB.

Authors:  Dos D Sarbassov; Siraj M Ali; Shomit Sengupta; Joon-Ho Sheen; Peggy P Hsu; Alex F Bagley; Andrew L Markhard; David M Sabatini
Journal:  Mol Cell       Date:  2006-04-06       Impact factor: 17.970

6.  Rapamycin inhibits smooth muscle cell proliferation and obstructive arteriopathy attributable to elastin deficiency.

Authors:  Wei Li; Qingle Li; Lingfeng Qin; Rahmat Ali; Yibing Qyang; May Tassabehji; Barbara R Pober; William C Sessa; Frank J Giordano; George Tellides
Journal:  Arterioscler Thromb Vasc Biol       Date:  2013-03-14       Impact factor: 8.311

7.  Pathology of coronary arteries, myocardium, and great arteries in supravalvular aortic stenosis. Report of five cases with implications for surgical treatment.

Authors:  J A van Son; W D Edwards; G K Danielson
Journal:  J Thorac Cardiovasc Surg       Date:  1994-07       Impact factor: 5.209

Review 8.  Risk of sudden death in the Williams-Beuren syndrome.

Authors:  Armin Wessel; Verena Gravenhorst; Reiner Buchhorn; Angela Gosch; Carl-Joachim Partsch; Rainer Pankau
Journal:  Am J Med Genet A       Date:  2004-06-15       Impact factor: 2.802

9.  Reduction of NADPH-oxidase activity ameliorates the cardiovascular phenotype in a mouse model of Williams-Beuren Syndrome.

Authors:  Victoria Campuzano; Maria Segura-Puimedon; Verena Terrado; Carolina Sánchez-Rodríguez; Mathilde Coustets; Mauricio Menacho-Márquez; Julián Nevado; Xosé R Bustelo; Uta Francke; Luis A Pérez-Jurado
Journal:  PLoS Genet       Date:  2012-02-02       Impact factor: 5.917

10.  Integrin β3 inhibition is a therapeutic strategy for supravalvular aortic stenosis.

Authors:  Ashish Misra; Abdul Q Sheikh; Abhishek Kumar; Jiesi Luo; Jiasheng Zhang; Robert B Hinton; Leslie Smoot; Paige Kaplan; Zsolt Urban; Yibing Qyang; George Tellides; Daniel M Greif
Journal:  J Exp Med       Date:  2016-02-08       Impact factor: 14.307

View more
  14 in total

Review 1.  Modeling elastin-associated vasculopathy with patient induced pluripotent stem cells and tissue engineering.

Authors:  Matthew W Ellis; Jiesi Luo; Yibing Qyang
Journal:  Cell Mol Life Sci       Date:  2018-11-20       Impact factor: 9.261

Review 2.  Hypertension in Children and Adolescents with Turner Syndrome (TS), Neurofibromatosis 1 (NF1), and Williams Syndrome (WS).

Authors:  Ramya Sivasubramanian; Kevin E Meyers
Journal:  Curr Hypertens Rep       Date:  2021-03-29       Impact factor: 5.369

Review 3.  Caught between a "Rho" and a hard place: are CCN1/CYR61 and CCN2/CTGF the arbiters of microvascular stiffness?

Authors:  Brahim Chaqour
Journal:  J Cell Commun Signal       Date:  2019-08-02       Impact factor: 5.782

4.  Reporting Sex and Sex Differences in Preclinical Studies.

Authors:  Hong S Lu; Ann Marie Schmidt; Robert A Hegele; Nigel Mackman; Daniel J Rader; Christian Weber; Alan Daugherty
Journal:  Arterioscler Thromb Vasc Biol       Date:  2018-10       Impact factor: 8.311

Review 5.  Elastin, arterial mechanics, and cardiovascular disease.

Authors:  Austin J Cocciolone; Jie Z Hawes; Marius C Staiculescu; Elizabeth O Johnson; Monzur Murshed; Jessica E Wagenseil
Journal:  Am J Physiol Heart Circ Physiol       Date:  2018-04-06       Impact factor: 4.733

6.  Whole exome sequencing in patients with Williams-Beuren syndrome followed by disease modeling in mice points to four novel pathways that may modify stenosis risk.

Authors:  Phoebe C R Parrish; Delong Liu; Russell H Knutsen; Charles J Billington; Robert P Mecham; Yi-Ping Fu; Beth A Kozel
Journal:  Hum Mol Genet       Date:  2020-07-29       Impact factor: 6.150

7.  Aortic Strain Correlates with Elastin Fragmentation in Fibrillin-1 Hypomorphic Mice.

Authors:  Jeff Z Chen; Hisashi Sawada; Jessica J Moorleghen; Mackenzie Weiland; Alan Daugherty; Mary B Sheppard
Journal:  Circ Rep       Date:  2019-04-27

Review 8.  Williams syndrome.

Authors:  Beth A Kozel; Boaz Barak; Chong Ae Kim; Carolyn B Mervis; Lucy R Osborne; Melanie Porter; Barbara R Pober
Journal:  Nat Rev Dis Primers       Date:  2021-06-17       Impact factor: 65.038

9.  Regulatory role of mammalian target of rapamycin signaling in exosome secretion and osteogenic changes in smooth muscle cells lacking acid ceramidase gene.

Authors:  Owais M Bhat; Xinxu Yuan; Rakesh C Kukreja; Pin-Lan Li
Journal:  FASEB J       Date:  2021-07       Impact factor: 5.834

10.  Everolimus Rescues the Phenotype of Elastin Insufficiency in Patient Induced Pluripotent Stem Cell-Derived Vascular Smooth Muscle Cells.

Authors:  Caroline Kinnear; Rahul Agrawal; Caitlin Loo; Aric Pahnke; Deivid Carvalho Rodrigues; Tadeo Thompson; Oyediran Akinrinade; Samad Ahadian; Fred Keeley; Milica Radisic; Seema Mital; James Ellis
Journal:  Arterioscler Thromb Vasc Biol       Date:  2020-03-26       Impact factor: 8.311

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.